Focus: Spectrum Dynamics is a public biotechnology company specializing in advanced cardiac and neurological imaging technologies, with a mid-cap footprint of 201-500 employees based in Sarasota, FL. The company was founded in 2021 and operates across multiple therapeutic areas including cardiovascular, hematology, and neurology.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Spectrum Dynamics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Only approved branded product generating all current company revenue; modest Part D uptake suggests limited blockbuster potential but provides near-term cash flow.
Help build intelligence for Spectrum Dynamics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Spectrum Dynamics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Monoclonal antibody radioconjugate approaching loss of exclusivity; limited revenue data suggests modest commercial performance.
Established chemotherapy generic approaching LOE with no apparent differentiation; minimal revenue contribution expected.
Post-LOE generic with no exclusivity; minimal commercial value.
2 discontinued, 0 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
A deep-learning noise reduction algorithm outperforms the spatial filters previously required for bone SPECT on a high-speed whole-body 360° CZT-camera.
Assessment of sestamibi CZT-SPECT reconstructed using deep-learning-based virtual attenuation correction maps according to coronary artery territory and with comparison to rubidium-PET.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo